Abstract library

22 results for "Molè".
#1821 Long-Term Efficacy and Safety with Lanreotide Autogel/Depot (LAN) from CLARINET and Open-Label Extension (OLE) Studies
Introduction: LAN 120mg has been shown to significantly prolong progression-free survival (PFS) in patients (pts) with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Professor Alexandria T. Phan
Authors: Phan A T, Pavel M, Caplin M, Wolin E M, ...
Keywords: lanreotide
#1185 Lanreotide Autogel (LAN) 120 mg in Patients with Progressive Enteropancreatic (EP-) NETs: Data from the CLARINET Open-Label Extension (OLE) Study
Introduction: In the CLARINET core study, LAN 120 mg significantly prolonged PFS vs placebo (PBO) in metastatic grade 1 or 2 EP-NETs.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
#2115 Systemic Markers of Inflammation in Neuroendocrine Tumors (NETs) and Outcomes with Everolimus: A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Introduction: NETs are extremely heterogeneous in nature. Despite recent advances, few biomarkers are available to consistently predict prognosis and optimize treatment selection.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: David L Chan
#1188 Antitumor Treatment with Lanreotide Autogel 120 mg (LAN) for Enteropancreatic (EP-)NET: Update from the CLARINET Open-Label Extension (OLE) Study
Introduction: In CLARINET, LAN had significant antitumour effects vs placebo (PBO) on metastatic G1/G2 EP-NETs, liver burden ≤ and >25%, and 96% SD prior to LAN.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Martyn Caplin
Authors: Caplin M, Pavel M, Cwikla J B, Phan A T, ...
#1811 Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies
Introduction: Two randomized double-blind (DB) trials demonstrated the efficacy of LAN 120mg/4weeks vs placebo in NETs: PFS improved in metastatic non-functioning intestinal/pancreatic NETs (CLARINET); less rescue medication used for carcinoid syndrome (CS) (ELECT).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Alexandria T Phan
Keywords: Lanreotide, safety
#2112 Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials
Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Nicola Fazio
Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, ...
#2297 Merkel Cell Carcinomas in New Zealand: Virus or Ultra Violet?
Introduction: Merkel Cell Carcinoma (MCC) is a rare Neuroendocrine skin tumour. MCC behavior is more aggressive than the more common Melanoma, with treatments often restricted to surgery or radiotherapy, although immunotherapy holds promise overseas. In 2008, a USA study identified an oncogenic polyomavirus (MCPyV) present in eight of ten tested MCC tumours. Studies from across Europe and the USA confirmed MCPyV presence in ~80% of all MCCs. However, a cohort from Australia found a rate of just 24%, suggesting an alternative mechanism; ultra violet (UV) exposure was suspected and later confirmed using genomic mutational signature analysis. Are these are two separate diseases, requiring different clinical management strategies for best patient outcomes?
Conference: 15th Annual ENETS conference (2018)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Tamsin Robb
Authors: Robb T, Woodhouse B, Parker K, Miller R, ...
#1175 Population Pharmacokinetic (PK) Analysis of Lanreotide Autogel (LAN) in the Treatment of Patients (pts) with NETs: Pooled Analysis of Four Clinical Trials
Introduction: LAN provide antitumor effects and symptom control in NET pts.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Nuria Buil-Bruna
Keywords: PK, dosing
#1942 Telotristat Ethyl in Carcinoid Syndrome: Safety and Efficacy Results of an Open-Label Extension of the TELECAST Phase 3 Clinical Trial
Introduction: TELECAST assessed telotristat ethyl (TE), a tryptophan hydroxylase inhibitor, in patients (pts) with carcinoid syndrome (CS) with ≥1 CS symptom/sign and a mean 2.5 bowel movements (BMs) per day. Pts were somatostatin analog treated (89%), with gastrointestinal (90%; [diarrhea, 70%]) and cardiac disorders (42%), including carcinoid heart disease. At Week (W) 12, TE (250 and 500 mg 3×/day; tid) significantly reduced urinary 5-hydroxyindoleacetic acid (u5-HIAA) and BMs/day vs placebo (pbo) (p≤0.008). After W12, pts crossed over to an open-label extension (OLE) with TE 500 mg tid (W13–48).
Conference: 14th Annual ENETS conference (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr. Marianne Pavel
Keywords: serotonin, safety
#308 Goblet Cell Carcinoid Tumors - A Retrospective Study of Clinical Presentation and Survival
Introduction: Goblet cell carcinoids (GCC) are rare mixed tumors, with partial neuroendocrine differentiation and intestinal-type goblet cell morphology. They usually have a highly malignant potential.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Henning Grønbæk
Authors: Holt N, Villadsen G, Krogh K, Olesen R, ...